1. Inici
  2. Publicacions
  3. Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Recasens-Zorzo, C
  • Cardesa-Salzmann, T
  • Petazzi, P
  • Ros-Blanco, L
  • Esteve-Arenys, A
  • Clot, G
  • Guerrero-Hernandez, M
  • Rodriguez, V
  • Soldini, D
  • Valera, A
  • Moros, A
  • Climent, F
  • Gonzalez-Barca, E
  • Mercadal, S
  • Arenillas, L
  • Calvo, X
  • Mate, JL
  • Gutierrez-Garcia, G
  • Casanova, I
  • Mangues, R
  • Bueno, C
  • Menendez, P
  • Martinez, A
  • Colomer, D
  • Tejedor, RE
  • Teixido, J
  • Campo, E
  • Lopez-Guillermo, A
  • Borrell, JI
  • Colomo, L
  • Perez-Galan, P
  • Roui, G

Grups d'Investigació

Abstract

Constitutive activation of the chemokine receptor CXCR4 has be en associated with tumor progression, invasion, and chemotherapy resistance in different cancer subtypes. Although the CXCR4 pathway has recently been suggested as an adverse prognostic marker in diffuse large B-cell lymphoma, its biological relevance in this disease remains underexplored. In a homogeneous set of 52 biopsies from patients, an antibody-based cytokine array showed that tissue levels of CXCL12 correlated with high microvessel density and bone marrow involvement at diagnosis, supporting a role for the CXCL12-CXCR4 axis in disease progression. We then identified the tetra-amine IQS-01.01RS as a potent inverse agonist of the receptor, preventing CXCL12-mediated chemotaxis and triggering apoptosis in a panel of 18 cell lines and primary cultures, with superior mobilizing properties in vivo than those of the standard agent. IQS-01.01RS activity was associated with downregulation of p-AKT, p-ERK1/2 and destabilization of MYC, allowing a synergistic interaction with the bromodomain and extra-terminal domain inhibitor, CPI203. In a xenotransplant model of diffuse large B-cell lymphoma, the combination of IQS-01.01RS and CPI203 decreased tumor burden through MYC and p-AKT downregulation, and enhanced the induction of apoptosis. Thus, our results point out an emerging role of CXCL12-CXCR4 in the pathogenesis of diffuse large B-cell lymphoma and support the simultaneous targeting of CXCR4 and bromodomain proteins as a promising, rationale-based strategy for the treatment of this disease.

Dades de la publicació

ISSN/ISSNe:
0390-6078, 1592-8721

HAEMATOLOGICA  FERRATA STORTI FOUNDATION

Tipus:
Article
Pàgines:
778-788
PubMed:
29954928
Factor d'Impacte:
2,931 SCImago ℠
Quartil:
Q1 SCImago ℠

Cites Rebudes en Web of Science: 19

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • IN-VIVO MODELS; CHEMOKINE RECEPTORS; ANTITUMOR-ACTIVITY; LEUKEMIA CELLS; EXPRESSION; MICROENVIRONMENT; MYC; LENALIDOMIDE; ANGIOGENESIS; DISCOVERY

Campos d'Estudi

Projectes associats

PROGRAMA I+D RAMON Y CAJAL.

Investigador Principal: ALEJANDRA SANJUAN PLA

RYC-2015-17534 . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2017

CELL OF ORIGIN/LEUKEMIA INITIATING CELL IN INFANT PRO-B MLL-AF4+ ACUTE LYMPHOBLASTIC LEUKEMIA.

Investigador Principal: ALEJANDRA SANJUAN PLA

631171 . COMISION EUROPEA . 2017

SPLICING Y EPIGENÉTICA EN SMD. Uso de modelos crispr/cas9 para estudiar el impacto de mutaciones genéticas y epigenéticas co-ocurrentes en los síndromes mielodisplásicos.

Investigador Principal: ALEJANDRA SANJUAN PLA

SAF2017-82171-R . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD . 2018

Papel de las alteraciones epigenéticas y del splicing en los Síndromes Mielodisplásicos.

Investigador Principal: ALEJANDRA SANJUAN PLA

ACIF/2018/255 . CONSELLERIA DE EDUCACION . 2018

Desarrollo de nuevos modelos murinos para los síndromes mielodisplásicos.

Investigador Principal: ALEJANDRA SANJUAN PLA

2018_362_CRC_SANJUAN . FUNDACIÓN BBVA . 2018

Compartir la publicació